Reviewing IN8bio (NASDAQ:INAB) and Calidi Biotherapeutics (NYSE:CLDI)

IN8bio (NASDAQ:INAB) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for IN8bio and Calidi Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	0	0	2	0	3.00
Calidi Biotherapeutics	0	0	3	0	3.00

IN8bio presently has a consensus price target of $10.00, indicating a potential upside of 4,173.50%. Calidi Biotherapeutics has a consensus price target of $16.67, indicating a potential upside of 1,487.30%. Given IN8bio’s higher possible upside, research analysts plainly believe IN8bio is more favorable than Calidi Biotherapeutics.

Insider and Institutional Ownership

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. 15.5% of IN8bio shares are owned by company insiders. Comparatively, 34.5% of Calidi Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares IN8bio and Calidi Biotherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$30.01 million	($0.91)	-0.26
Calidi Biotherapeutics	$50,000.00	1,069.40	-$29.22 million	N/A	N/A

Calidi Biotherapeutics has higher revenue and earnings than IN8bio.

Profitability

This table compares IN8bio and Calidi Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-173.12%	-118.40%
Calidi Biotherapeutics	N/A	N/A	-219.07%

Volatility & Risk

IN8bio has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Summary

Calidi Biotherapeutics beats IN8bio on 6 of the 9 factors compared between the two stocks.

About IN8bio

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.